Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy.
Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy.
复制标题
肝细胞癌精准医疗：驱动突变与靶向治疗
DOI：
10.18632/oncotarget.18382
复制
发表时间：
2017-08-15
期刊：
影响因子：
--
通讯作者：
Zhang HQ
中科院分区：
文献类型：
--
作者：
Ding XX;Zhu QG;Zhang SM;Guan L;Li T;Zhang L;Wang SY;Ren WL;Chen XM;Zhao J;Lin S;Liu ZZ;Bai YX;He B;Zhang HQ
肝细胞癌是与肿瘤相关的死亡的第三大常见原因，估计每年约有850,000例新病例。大多数肝细胞癌患者被诊断为中晚期，失去了手术机会。肝癌的发展是由累积的各种基因突变推动的，这些突变赋予肿瘤细胞选择性生长的优势，被称为驱动突变。驱动基因突变的发现为晚期肝癌提供了一种新的精准药物治疗策略，称为靶向治疗。本文综述了目前已发现的驱动基因突变和相应的信号通路，综述了驱动基因突变和基因的识别方法，并对肝癌靶向药物进行了分类。突变景观的知识加深了我们对癌症发生的理解，并有望为肝癌患者提供未来的精准医学。
Hepatocellular carcinoma (HCC) is the third most frequent cause of tumor-related mortality and there are an estimated approximately 850,000 new cases annually. Most HCC patients are diagnosed at middle or advanced stage, losing the opportunity of surgery. The development of HCC is promoted by accumulated diverse genetic mutations, which confer selective growth advantages to tumor cells and are called “driver mutations”. The discovery of driver mutations provides a novel precision medicine strategy for late stage HCC, called targeted therapy. In this review, we summarized currently discovered driver mutations and corresponding signaling pathways, made an overview of identification methods of driver mutations and genes, and classified targeted drugs for HCC. The knowledge of mutational landscape deepen our understanding of carcinogenesis and promise future precision medicine for HCC patients.
登录
查看更多内容
影响因子：
2.9
作者：
Campbell, Jean S.;Johnson, Melissa M.;Fausto, Nelson
通讯作者：
Fausto, Nelson
DOI：
10.1073/pnas.0409722102
发表时间：
2005-03-01
影响因子：
11.1
作者：
Campbell, JS;Hughes, SD;Fausto, N
通讯作者：
Fausto, N
影响因子：
4.4
作者：
Gnad F;Baucom A;Mukhyala K;Manning G;Zhang Z
通讯作者：
Zhang Z
影响因子：
168.9
作者：
Bruix, Jordi;Qin, Shukui;Han, Guohong
通讯作者：
Han, Guohong
索拉非尼对亚太地区晚期肝细胞癌患者的疗效和安全性：一项 III 期随机、双盲、安慰剂对照试验
影响因子：
51.1
作者：
Cheng, Ann-Lii;Kang, Yoon-Koo;Guan, Zhongzhen
通讯作者：
Guan, Zhongzhen